Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists
Two newer diabetes drugs show equivalent psychiatric safety while one demonstrates substantially lower suicide-related events than older alternatives.
This large real-world active-comparator study used 192-million-patient federated data to match 85,546 tirzepatide-semaglutide pairs and 80,115 semaglutide-vs-older-GLP-1 pairs for neuropsychiatric safety evaluation. Tirzepatide and semaglutide carried equivalent psychiatric risk at 2 years, while semaglutide demonstrated markedly lower psychiatric event rates versus older agents including a 51% lower suicidal ideation hazard.
What the study was
- Study design
- retrospective_cohort_active_comparator
- Category
- cardiovascular_metabolic
- Maturity
- Validated
- Journal
- Diabetes Obes Metab
Why it surfaced
Critical active-comparator safety study on psychiatric risk of newest GLP-1 agents in the largest real-world comparative dataset to date; directly actionable for prescribing decisions; high policy and pharmacovigilance relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.